Nektar Therapeutics Reports Financial Results for Q1 2025
Nektar Therapeutics (NASDAQ: NKTR) has recently shared its financial performance results for the first quarter of 2025. The company reported that cash and investments in marketable securities were $220.7 million as of March 31, 2025. This shows a decrease from $269.1 million noted at the end of 2024. The available resources are expected to support strategic development activities and operations into late 2026.
"We are excited to announce that we will share topline data in June from our Phase 2 study of rezpegaldesleukin targeting atopic dermatitis," stated Howard W. Robin, President and CEO of Nektar. "Following this, we anticipate topline data from the Phase 2 study focusing on patients with alopecia areata by December. These results aim to show the significant potential that rezpegaldesleukin offers as a new treatment option for patients suffering from severe skin conditions."
Nektar Therapeutics is also advancing its unique antibody NKTR-0165, which targets the TNFR2 receptor. This therapeutic candidate could provide novel treatment avenues for conditions like multiple sclerosis and vitiligo. The team aims to submit an Investigational New Drug (IND) application for NKTR-0165 by the end of this calendar year. Significant strides are also being made in the development of a new bispecific antibody, NKTR-0166, which progresses to preclinical testing.
Key Financial Highlights
In the first quarter of 2025, Nektar reported a total revenue of $10.5 million, compared to $21.6 million in the same quarter of the previous year. This decrease in revenue is attributed to the cessation of product sales following the sale of its Huntsville manufacturing facility in December 2024.
The overall operating costs and expenses were recorded at $55.0 million, reflecting a decrease from $57.1 million in Q1 2024. The reduction in operating expenses primarily stemmed from the eliminated cost of goods sold, balanced out by increased research and development (R&D) and general administrative (G&A) expenses.
In detail, R&D expenses surged to $30.5 million in Q1 2025, up from $27.4 million from the previous year, mainly due to intensified efforts on the development of rezpegaldesleukin. One notable offset was the decrease in expenses for NKTR-255 development.
The G&A expenses increased to $24.3 million from $20.1 million in Q1 2024, primarily driven by rising legal costs despite some reductions in facility and stock-based compensation expenses.
Nektar initiated investment accounting for Gannet BioChem according to the equity method, leading to a non-cash loss of $4.5 million from this investment. The net loss for Q1 was $50.9 million or $0.24 per share compared to a net loss of $36.8 million or $0.19 per share in Q1 of the previous year. Excluding the noted non-cash loss, the non-GAAP net loss was reported at $46.4 million or $0.22 per share.
Recent Advancements and Achievements
In April 2025, a pivotal moment occurred when the European Hematological Association selected an Nektar abstract for oral presentation regarding the synergistic effects of NKTR-255 in CAR T-cell therapies. This presentation is set to take place during the 30th annual EHA Congress.
During February 2025, the company achieved target enrollment in a significant 84-patient Phase 2 clinical trial studying rezpegaldesleukin in severe alopecia areata. A partnership with TrialNet is aimed at testing rezpegaldesleukin on around 70 new type 1 diabetes patients in a Phase 2 trial.
The FDA granted Fast Track designation to rezpegaldesleukin for the treatment of moderate-to-severe atopic dermatitis in patients whose condition is inadequately managed with current therapies, marking a significant milestone for the therapy.
In January 2025, Nektar completed the target enrollment for a 396-patient Phase 2b trial of rezpegaldesleukin aimed at moderate-to-severe atopic dermatitis, further showcasing its commitment to innovative breakthroughs in treatments.
Upcoming Engagements and Events
Nektar Therapeutics management has scheduled a conference call to discuss the financial results for the first quarter of 2025. Investors and interested stakeholders can tune in to the live call at 5:00 PM Eastern Time. Those interested are encouraged to register in advance through the company’s official channels.
About Nektar Therapeutics
Nektar Therapeutics operates as a clinical-stage biotechnology organization dedicated to developing transformative therapies for autoimmune and chronic inflammatory diseases. Its flagship product, rezpegaldesleukin, is a first-in-class T cell stimulator actively evaluated in multiple Phase 2b clinical trials targeting critical health conditions. As part of its broad pipeline, Nektar is advancing several innovative drug candidates with strategic collaborations.
Frequently Asked Questions
What are the key financial results reported by Nektar for Q1 2025?
Nektar reported a total revenue of $10.5 million for the first quarter, alongside a net loss of $50.9 million.
What is rezpegaldesleukin?
Rezpegaldesleukin is Nektar's lead therapeutic candidate targeting autoimmune disorders, currently in clinical trials for atopic dermatitis and alopecia areata.
How does Nektar plan to utilize its cash reserves?
Nektar's cash reserves, totaling $220.7 million, are intended to support strategic development initiatives and business operations through late 2026.
What recent advancements have been made in Nektar's clinical trials?
Nektar has recently completed target enrollment for various significant clinical trials focusing on rezpegaldesleukin and has been granted Fast Track designation by the FDA.
Where can investors find information on upcoming financial calls?
Investors can access information about upcoming financial calls and related events through Nektar's official website and investor relations pages.
